Liver metastases occupy a uniquely punishing position in the natural history of breast cancer. While modern HER2-targeted therapies—starting with trastuzumab and extending through pertuzumab, lapatinib, tucatinib and trastuzumab deruxtecan—have transformed median survival for HER2-positive disease overall, patients whose cancer has seeded the liver have consistently fared worse than those with metastatic disease confined to other sites. The liver’s dual blood supply, immunosuppressive microenvironment and frequent involvement in drug-resistant clones all contribute to poorer responses to systemic therapy. For this reason, the liver has long been regarded as a sanctuary-like site where conventional regimens lose much of their effectiveness, and the demonstration that a novel agent can meaningfully alter outcomes specifically in this subgroup carries implications well beyond a routine incremental advance.

Disitamab vedotin, also known by its development code RC48, belongs to a class of therapeutics that has become one of the most active frontiers in oncology: the antibody–drug conjugate, or ADC. These molecules are engineered to combine the targeting specificity of a monoclonal antibody with the cell-killing potency of a cytotoxic payload, linked through a chemical connector designed to remain stable in circulation but cleavable once the construct reaches the tumor. Disitamab vedotin pairs a humanized anti-HER2 antibody, disitamab, with monomethyl auristatin E (MMAE), a synthetic analog of molecules derived from marine shellfish toxins that disrupts microtubule assembly and drives apoptotic cell death during cell division. The antibody is conjugated to the payload through a valine-citrulline linker that is cleaved by cathepsin B, a protease enriched in lysosomes, releasing MMAE preferentially within HER2-expressing tumor cells.

What distinguishes disitamab vedotin from earlier ADCs built on the same general blueprint is its drug-to-antibody ratio and its binding characteristics. The conjugation chemistry yields an average of approximately four MMAE molecules per antibody, a higher degree of drug loading than the roughly three-to-four achieved by first-generation breast cancer ADCs but achieved with a more homogeneous attachment strategy that reduces batch-to-batch variability. The antibody itself recognizes a distinct epitope on the extracellular domain of HER2 compared with trastuzumab, which may allow the drug to bind tumor cells even when HER2 expression levels or conformations have shifted under the pressure of prior anti-HER2 treatment. Once internalized, each antibody can deliver a concentrated cytotoxic payload, and a degree of bystander killing—release of membrane-permeable MMAE that diffuses to neighboring tumor cells regardless of their own HER2 density—adds a second layer of antitumor activity. This bystander effect is considered particularly valuable in heterogeneous tumors, where patches of low-HER2 cells can otherwise survive selective pressure and seed resistance.

The RC48-C006 study was designed as a phase 2/3 program, with the pivotal phase 3 portion enrolling patients with HER2-positive breast cancer and liver metastases who had progressed on prior lines of systemic therapy. Participants were randomized to receive disitamab vedotin or comparator chemotherapy, and the trial measured objective response rate and progression-free survival as its primary efficacy endpoints, alongside overall survival and safety. In the reported results, patients treated with disitamab vedotin achieved markedly higher response rates than those receiving standard chemotherapy, with a substantial fraction of tumors shrinking measurably on imaging. Progression-free survival, the time patients live without their disease worsening, was significantly extended, and early overall survival signals pointed in the same direction. The magnitude of benefit in a liver-dominant population—a setting in which even modern regimens often struggle—is the most consequential aspect of the data.

Safety findings tracked the established profile of MMAE-based ADCs. The most commonly observed adverse events included reductions in white blood cell counts, peripheral sensory neuropathy manifested as numbness or tingling in the hands and feet, elevated liver enzymes, hair loss, and gastrointestinal symptoms such as nausea. These toxicities were predominantly manageable with dose modification and supportive care, and the rate of treatment discontinuation due to adverse events remained at a level consistent with clinical practice. Interstitial lung disease, the feared complication associated with some newer ADC platforms, was monitored closely and appeared uncommon in this program. The investigators emphasize that the risk–benefit calculus in a population with few remaining options weighs favorably toward active treatment, though they note that neuropathy in particular warrants proactive monitoring in longer-term survivors.

The significance of the trial extends to its patient selection strategy. HER2 positivity in breast cancer is defined by immunohistochemistry and in situ hybridization testing, and disitamab vedotin has shown activity across a range of HER2 expression levels in earlier studies, including tumors classified as HER2-low. By focusing the phase 3 on unequivocally HER2-positive disease with liver involvement, the investigators targeted the population with the highest unmet need and the clearest biological rationale. The stratification by metastatic site also adds analytic power: rather than enrolling a mixed metastatic population in which liver metastases form a small, underpowered subgroup, RC48-C006 was built from the ground up to answer the question of whether the drug works in this specific, difficult setting. That design choice, still relatively rare in oncology trials, allows the findings to be translated directly into clinical decision-making for patients whose imaging shows hepatic disease.

The mechanistic story underlying the results is one of targeted delivery amplifying an old chemotherapy. MMAE belongs to the auristatin family, molecules that bind tubulin at the vinca alkaloid site and block polymerization into microtubules, the structural scaffolds that cells require to divide. Free MMAE is far too toxic for systemic administration, which is precisely why conjugation to an antibody matters. The therapeutic window emerges from differential exposure: tumor cells that overexpress HER2 internalize hundreds of thousands to millions of antibody molecules per cell, concentrating the payload where it is needed, while circulating antibody largely spares normal tissues that express little or no HER2. Some HER2 is present on cardiac muscle cells, which is why HER2-targeted agents historically raised cardiotoxicity concerns, but the cardiac monitoring in this trial reflected acceptable cardiac safety, consistent with the lower rate of cardiotoxicity seen with ADC platforms compared with prolonged trastuzumab-based blockade.

The results arrive at a moment of intense competition and collaboration in the HER2-directed ADC field, as drugs such as trastuzumab deruxtecan have already demonstrated that payload delivery through HER2 targeting can overcome resistance to older therapies. Disitamab vedotin’s contribution is to extend that paradigm with a distinct antibody, linker and payload combination, and to validate it in a population—HER2-positive disease with liver metastases—where head-to-head level 1 evidence has been scarce. Beyond breast cancer, the agent has been investigated in urothelial carcinoma, gastric cancer and other HER2-expressing tumors, and regulatory approvals in parts of Asia have already been based on earlier-phase evidence. The phase 3 data in liver-metastatic breast cancer now give the drug its strongest evidentiary foundation to date and are likely to inform discussions with regulatory agencies in additional jurisdictions.

For patients and clinicians, the immediate question is sequencing: where disitamab vedotin fits among trastuzumab deruxtecan, tucatinib combinations and other options in the expanding HER2-positive arsenal. Cross-trial comparisons are notoriously unreliable, and the investigators and independent commentators alike caution that only randomized head-to-head studies can determine optimal ordering of the newer agents. What RC48-C006 establishes is that liver metastases need not consign patients to uniformly inferior outcomes, and that an ADC engineered with a Chinese-developed antibody, a protease-cleavable linker and a microtubule-disrupting payload can deliver clinically meaningful benefit precisely where the disease is most resistant. As follow-up matures and overall survival data accumulate, the trial is expected to serve as a reference point for the next generation of studies aimed at the metastatic sites where breast cancer still claims its greatest toll. The study, authored by Wang, Ouyang, Xie and colleagues, was published in Nature Communications in 2026.

Published in The Lancet on Aug. 6, the findings could reshape treatment for patients whose cancer has recently spread and has received little or no prior systemic therapy. The results supported the U.S. Food and Drug Administration’s approval in late July of lutetium Lu-177 vipivotide tetraxetan, also known as ^177Lu-PSMA-617, for earlier use alongside an androgen receptor pathway inhibitor and androgen deprivation therapy.

Metastatic prostate cancer is commonly driven by male sex hormones, particularly testosterone and related androgens. For that reason, the standard treatment backbone has typically combined androgen deprivation therapy, which suppresses the body’s production of testosterone, with an androgen receptor pathway inhibitor, which blocks cancer cells from responding to residual hormonal signals. Although this approach can control disease for a time, resistance eventually develops in many patients. The PSMAddition trial tested whether introducing a targeted radiopharmaceutical before resistance emerges could extend that period of control.

The study enrolled more than 1,100 men with PSMA-positive metastatic prostate cancer at 169 sites in 20 countries. Approximately half received intravenous ^177Lu-PSMA-617 every six weeks in addition to androgen deprivation therapy and an androgen receptor pathway inhibitor. The other participants received the hormonal treatment combination alone, representing the previous standard of care. Patients in the control group were permitted to cross over to the three-drug regimen if their disease progressed, a design that allowed them access to the investigational treatment while preserving the trial’s ability to compare initial treatment strategies.

The radiopharmaceutical works through a molecular targeting system. PSMA is a protein found at high levels on the surface of most prostate cancer cells; according to the investigators, roughly nine in ten patients with metastatic prostate cancer have PSMA-positive tumors. ^177Lu-PSMA-617 consists of a PSMA-binding molecule chemically linked to lutetium-177, a radioactive isotope. After the drug binds to PSMA, it is taken toward or into the tumor cell, where the isotope emits beta radiation. This radiation damages nearby cellular DNA, helping destroy malignant cells while limiting exposure to tissues that carry little or no PSMA.

The trial’s primary result was radiographic progression-free survival, which measures how long patients live without visible growth or spread of cancer on imaging or death from any cause. Early addition of ^177Lu-PSMA-617 extended this interval compared with hormonal treatment alone. The investigators also reported that the drug delayed the development of castration-resistant disease, the stage at which prostate cancer continues progressing despite testosterone suppression. In addition, patients receiving the targeted radiotherapy experienced a longer interval before cancer-related symptoms involving the skeleton appeared.

Bone complications are a major concern in advanced prostate cancer because the disease frequently spreads to the skeleton. Tumors in bone can cause pain, fractures, spinal cord compression and other disabling problems. By delaying skeletal symptoms, the treatment may preserve quality of life as well as postpone the need for subsequent therapies. However, the researchers emphasized that longer follow-up is still needed to determine whether the early progression benefit will translate into a statistically confirmed improvement in overall survival.

The added treatment also brought additional side effects, as expected from a three-drug regimen that combines hormonal therapy with systemic radiation. Dry mouth was the most frequently reported adverse event, affecting 46% of patients who received ^177Lu-PSMA-617. The symptom occurs because salivary glands can express PSMA and may absorb some of the radiopharmaceutical. Fatigue was also common, reflecting the effects of both radiation and hormonal treatment. Physicians must weigh these risks against the potential benefit and monitor patients over time for less common or delayed complications.

The therapy is not suitable for every person with metastatic prostate cancer. Patients must first undergo specialized molecular imaging to confirm that their tumors contain sufficient PSMA for targeting. Administration requires nuclear medicine physicians or radiation oncologists, as well as facilities equipped to handle radioactive medicines. Treatment centers must also provide guidance on radiation safety, including precautions designed to reduce exposure to family members and others in the household. These requirements may make access more difficult for patients who live far from academic medical centers or specialized oncology programs.

The early success of ^177Lu-PSMA-617 follows earlier studies showing activity in patients whose metastatic prostate cancer had already become resistant to hormonal treatment. Its use at diagnosis represents a shift in strategy: rather than reserving targeted radiotherapy for advanced, treatment-resistant disease, clinicians may now deploy it while tumors remain more vulnerable to combined treatment. The PSMAddition investigators are continuing to analyze long-term survival and safety data. As additional molecular imaging agents and biomarker-driven therapies enter clinical practice, treatment selection is likely to become increasingly individualized, with the biology of each tumor helping determine which targeted drug is introduced, and when.

Subject of Research: Early use of targeted radionuclide therapy with ^177Lu-PSMA-617 in PSMA-positive metastatic prostate cancer.

News Publication Date: 6-Aug-2026

Web References: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-androgen-receptor-pathway-inhibitor-therapy; https://news.weill.cornell.edu/news/2017/05/first-clinical-trial-of-new-targeted-molecular-therapy-in-us-takes-aim-at-incurable

References: The Lancet; PSMAddition phase 3 clinical trial.

Keywords: Prostate cancer, metastatic prostate cancer, PSMA, ^177Lu-PSMA-617, lutetium vipivotide tetraxetan, targeted radionuclide therapy, radiopharmaceuticals, androgen deprivation therapy, androgen receptor pathway inhibitors, cancer treatment

Typhoid fever remains a formidable challenge to health systems in endemic areas, primarily affecting children under 15 but also posing risks across age groups. The causative agent, Salmonella Typhi, thrives in regions with inadequate sanitation infrastructure, and the emerging threat of antimicrobial resistance exacerbates the urgent need for efficacious vaccines. Against this backdrop, EuTYPH-C Inj.® Multi-dose offers renewed hope by meeting stringent international benchmarks for safety and immunogenicity, thereby promising enhanced protection and facilitating broader vaccine coverage.

This multicenter Phase 3 trial employed a randomized, observer-blind methodology encompassing over 3,200 healthy participants aged from six months to 45 years at two African sites—Kericho in Kenya and Sandiara in Senegal. Participants were administered either EuTYPH-C Inj.® Multi-dose or the World Health Organization (WHO)-prequalified Typbar TCV®. Comprehensive safety assessments revealed a tolerability profile for EuTYPH-C that was consistent with, if not superior to, the comparator vaccine, with no vaccine-related serious adverse events observed throughout the study duration.

Critically, immunogenicity evaluations centered on infants aged 9 to 12 months demonstrated that immune responses elicited by both single-dose and multi-dose formats of EuTYPH-C were not inferior to Typbar TCV®. High seroconversion rates were documented 28 days post-vaccination and sustained at six months, indicating durable antibody-mediated protection. Furthermore, EuTYPH-C displayed compatibility with the co-administration of measles-rubella and yellow fever vaccines—a significant finding that supports integrated immunization schedules without compromising immunologic efficacy.

Dr. Patricia Njuguna, the senior medical officer and project lead from PATH, emphasized the paramount importance of safety in vaccine deployment, underscoring that EuTYPH-C’s safety profile reassures its suitability for mass immunization campaigns across diverse age groups. The absence of serious adverse events related to the vaccine is notable, especially in pediatric cohorts where tolerability often dictates programmatic success.

The successful licensure of EuTYPH-C Inj.® Multi-dose by the Korean Ministry of Food and Drug Safety, bolstered by Phase 3 data, positions the vaccine for imminent submission to the WHO for prequalification. This designation is essential for procurement by UN agencies and Gavi, the Vaccine Alliance, which play critical roles in vaccine distribution to low- and middle-income countries. Increasing the portfolio of WHO-prequalified TCVs actively contributes to fostering competitive pricing, ensuring supply resiliency, and accelerating access to lifesaving immunizations.

EuBiologics, the manufacturer based in Seoul, has a commendable track record, including WHO prequalification of their oral cholera vaccine, highlighting their expertise in vaccine development and global health contributions. The introduction of EuTYPH-C into the typhoid vaccine market is anticipated to further diversify and stabilize supply chains, a vital consideration given the escalating demand in Gavi-supported countries where seven have already integrated TCVs into national immunization programs.

Typhoid remains a major public health threat, with more than 7 million cases and over 93,000 deaths estimated globally in 2021, predominantly in Asia and sub-Saharan Africa. Given the rise in drug-resistant strains of Salmonella Typhi, vaccination emerges as an indispensable preventive tool alongside improvements in water, sanitation, and hygiene infrastructure. Over 90 million doses of TCVs have already been administered globally, yet vaccine access and affordability continue to be barriers in many high-burden regions.

The robust immune responses observed with EuTYPH-C, its safety, and ability to be co-administered with other childhood vaccines underscore its potential for seamless integration into existing immunization schedules. Such integration is critical to optimizing healthcare delivery efficiencies and increasing vaccination coverage among vulnerable populations, particularly infants and young children who bear the highest disease burden.

This trial represents a successful collaboration among international stakeholders, including PATH, EuBiologics, Kenya Medical Research Institute (KEMRI), Walter Reed Army Institute of Research (WRAIR), and the Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF). Funding support from EuBiologics and the RIGHT Foundation underscores the importance of public-private partnerships in driving vaccine innovation and equitable health advancements globally.

Looking ahead, WHO prequalification of EuTYPH-C will enhance the vaccine’s availability for widespread use, potentially transforming typhoid prevention strategies in endemic countries. Expanding the vaccine arsenal is pivotal to combating the persistent challenges posed by typhoid fever, ultimately reducing morbidity and mortality, and contributing to the global agenda for vaccine-preventable disease control and elimination.

EuTYPH-C Inj.® Multi-dose exemplifies cutting-edge conjugate vaccine technology that leverages the Vi polysaccharide antigen coupled with CRM197 carrier protein to evoke a strong, persistent immune response. This immunological strategy addresses the limitations of earlier polysaccharide vaccines, which were less efficacious particularly in young children, by inducing T-cell-dependent immunity and immune memory—an essential feature for durable protection and herd immunity.

The trial’s rigorous design, encompassing lot-to-lot consistency and evaluation across various age cohorts, provides comprehensive data supporting the vaccine’s quality and effectiveness. Such robust scientific evidence is instrumental in informing policy makers, immunization programs, and global health stakeholders in their decisions to scale TCV deployment and optimize typhoid control efforts.

In summary, the publication of EuTYPH-C Inj.® Multi-dose Phase 3 clinical trial data marks a significant milestone in typhoid vaccine research and public health practice. This vaccine’s demonstrated safety, immunogenicity, and operational compatibility position it as a key addition to the international fight against typhoid fever, particularly within sub-Saharan Africa and other regions grappling with endemic disease and the rising threat of antimicrobial resistance.

Subject of Research: People

Article Title: A Multi-Center, Observer-Blind, Randomized, Phase 3 Study to Evaluate Safety, Non-Inferiority of Multi-Dose and Single-Dose Vial Formulations of EuTCV (Vi-CRM197 Typhoid Conjugate Vaccine) and Lot-to-Lot Consistency of the Immune Response to Multi-Dose Vial Formulation EuTCV in Healthy Participants in Kenya and Senegal

News Publication Date: 12-Nov-2025

Image Credits: Photo courtesy of EuBiologics Co., Ltd.

Keywords: Vaccine development, Vaccine research, Clinical research, Typhoid, Bacterial infections, Vaccination, Africa, Asia, Infectious diseases, Public health, Clinical trials, Preventive medicine

The E4512 trial enrolled patients diagnosed with surgically resected stage IIA through IIIB ALK-positive NSCLC, confirmed by fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), or next-generation sequencing (NGS). Importantly, participants had to meet strict inclusion criteria, including negative surgical margins ensuring complete tumor removal, an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1 denoting relatively preserved functional status, and no prior exposure to any ALK-targeted therapy. Participants were either assigned to active surveillance or crizotinib administered at a dosage of 250 mg twice daily for up to two years, barring disease recurrence or dose-limiting toxicity.

Over a nearly ten-year recruitment period extending from August 2014 to May 2024, the study accrued 166 evaluable patients, closely aligning with its initial target enrollment. The trial’s recruitment was ultimately halted following the U.S. Food and Drug Administration’s approval of alectinib as adjuvant therapy for resected ALK-positive NSCLC, which became the new standard of care and impacted the clinical equipoise necessary for the continuation of the study.

The primary endpoint of the trial was disease-free survival, a critical measure reflecting the time from surgery until cancer recurrence or death, while secondary endpoints included overall survival and safety profiles. After a median follow-up approaching five years (58.3 months), the data demonstrated no statistically significant difference in median DFS between the crizotinib and observation arms. Specifically, patients receiving crizotinib exhibited a median DFS of 72.8 months, slightly below the 75.1 months observed in the observation group, resulting in a hazard ratio (HR) of 1.06 with a wide confidence interval (90% CI: 0.63–1.77) and a high p-value, underscoring the lack of efficacy.

Overall survival data remain immature with median OS not reached in either arm at the time of reporting. Nonetheless, the hazard ratio for OS favored crizotinib numerically (HR 0.49), yet this finding did not achieve statistical significance (p=0.26), indicative of the need for longer follow-up before any definitive conclusions can be drawn regarding survival benefits.

The safety profile of adjuvant crizotinib mirrored known toxicities from prior metastatic NSCLC studies. Grade 3 adverse events were common, affecting roughly one-third of patients treated, with diarrhea and peripheral edema as the most frequent severe toxicities. Moreover, one patient tragically experienced a grade 4 stroke during treatment. Treatment-related adverse effects necessitated dose reductions in nearly a quarter of patients and led to permanent treatment discontinuation in 25%, highlighting the challenge of managing toxicity in the adjuvant setting where patients are potentially cured and generally asymptomatic.

These findings carry significant clinical and biological implications for the management of early-stage resected ALK-positive NSCLC. While crizotinib has revolutionized care for metastatic ALK-positive NSCLC over the last decade, its application in an adjuvant context appears futile according to this trial’s rigorous data. The lack of DFS benefit suggests that crizotinib’s pharmacodynamic and pharmacokinetic properties, or possibly its CNS penetration, may be inadequate to eradicate micrometastatic disease post-surgery.

In contrast, contemporary advances have established second-generation ALK inhibitors like alectinib as the preferred adjuvant agents, given their more favorable CNS activity and superior efficacy in advanced disease. Indeed, regulatory approval of adjuvant alectinib has set a new clinical standard, underscoring the importance of this study’s early termination and providing a sound rationale for clinicians to avoid crizotinib in this context despite its prior approval in metastatic disease stages.

From a molecular perspective, the heterogeneity of ALK rearrangements and the intrinsic resistance mechanisms may also contribute to the observed lack of effect. The ability of crizotinib to reach and sustain cytotoxic levels in potential sanctuary sites post-surgery might be limited. Furthermore, patient selection based on centralized confirmation of ALK status via robust techniques such as FISH, IHC, and NGS ensures the validity of the study population, yet the intrinsic biology of micrometastatic disease remains a formidable barrier.

This trial also reinforces the critical role of large, cooperative group studies embedded within national research initiatives such as the ALCHEMIST program, which rigorously evaluates the utility of targeted therapies in curative-intent settings. The methodological rigor of E4512, including randomized design, stratification, and comprehensive follow-up, exemplifies the gold standard for biomarker-driven trials aimed at personalized medicine in thoracic oncology.

In summation, the E4512 trial results decisively demonstrate that adjuvant crizotinib confers no DFS benefit in patients with resected early-stage ALK-positive NSCLC and is associated with meaningful toxicity. These findings emphasize the evolving paradigm in management where newer-generation ALK inhibitors, supported by more robust clinical data regarding efficacy and CNS penetration, command frontline use in the adjuvant setting.

This data was formally presented and peer-reviewed at the IASLC 2025 World Conference on Lung Cancer, reinforcing the importance of continued multidisciplinary collaboration and innovation in targeting molecular subsets of lung cancer. Moving forward, therapeutic strategies combining surgery with next-generation targeted agents and potentially immunotherapeutic approaches represent a promising horizon for improving outcomes in ALK-driven thoracic malignancies.

Subject of Research:
Adjuvant targeted therapy for resected ALK-positive non-small cell lung cancer

Article Title:
Crizotinib Fails to Improve Disease-Free Survival as Adjuvant Therapy in Early-Stage ALK-Positive NSCLC: Results from the Phase 3 E4512 Trial

News Publication Date:
September 7, 2025

Web References:
https://www.iaslc.org (International Association for the Study of Lung Cancer)

Keywords:
Lung cancer, non-small cell lung cancer, ALK-positive, crizotinib, adjuvant therapy, disease-free survival, ALK inhibitors, targeted therapy, phase 3 clinical trial, thoracic oncology